THERAPYX, INC.

Address

138 FARBER HALL
3435 MAIN STREET
BUFFALO, NY, 14214-8001

Information

DUNS: 145056607
# of Employees: 6

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Experimental Gonococcal Vaccine

    Amount: $805,248.00

    ABSTRACT Genital tract infection with Neisseria gonorrhoeae gonorrhea does not induce a state of specific protective immunity and it can be acquired repeatedly Despite public health measures the d ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD

    Amount: $999,998.00

    Abstract TGF NanoCap is an oral combination of nanoparticulate transforming growth factor beta TGF and all trans retinoic acid ATRA in pre clinical development for treatment of inflammatory b ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  3. Oral sustained-release IL-10 microspheres for therapy of IBD

    Amount: $295,831.00

    Abstract The disorders collectively known as inflammatory bowel disease IBD including Crohn s disease CD and ulcerative colitis UC affect up to one and a half million Americans Both result from ...

    SBIRPhase I2016Department of Health and Human Services
  4. Experimental Gonococcal Vaccine

    Amount: $271,000.00

    DESCRIPTION provided by applicant Genital tract infection with Neisseria gonorrhoeae gonorrhea does not induce a state of specific protective immunity and can be acquired repeatedly Despite publ ...

    SBIRPhase I2015Department of Health and Human Services
  5. Therapy and Prophylaxis for Genital Tract Infection

    Amount: $1,498,000.00

    DESCRIPTION provided by applicant Genital tract infection with Neisseria gonorrhoeae gonorrhea does not induce a state of specific protective immunity and can be acquired repeatedly Despite publ ...

    SBIRPhase II2014Department of Health and Human Services
  6. A novel, multiparametric cardiac safety assay using human myocytes

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Genital tract infection with Neisseria gonorrhoeae (gonorrhea) does not induce a state of specific protective immunity and can be acquired repeatedly. Despite publ ...

    SBIRPhase I2013Department of Health and Human Services
  7. Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD

    Amount: $2,999,994.00

    DESCRIPTION (provided by applicant): Phase I studies established proof-of-principle for the efficacy of oral sustained-release TGF?1 (TPX-6001) and ATRA (TPX-7001) nanoparticles in the treatment of IB ...

    SBIRPhase II2011Department of Health and Human Services
  8. Co-encapsulation of IroN and IL-12 as an Extra-intestinal E. coli Vaccine.

    Amount: $292,501.00

    DESCRIPTION (provided by applicant): Despite recent advances in the treatment and prevention of infectious disease, the threat to world health continues to grow. The spread of new zoonotic viral stra ...

    SBIRPhase I2008Department of Health and Human Services
  9. Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD

    Amount: $172,500.00

    DESCRIPTION (provided by applicant): The disorders collectively known as inflammatory bowel disease (IBD) include Crohn's disease (CD) and ulcerative colitis (UC) and affect up to one million people i ...

    SBIRPhase I2008Department of Health and Human Services
  10. Treatment of Type 2 Diabetes with Oral Administration of Nanoencapsulated GLP-1

    Amount: $144,961.00

    DESCRIPTION (provided by applicant): Type 2 diabetes mellitus is one of the leading causes of death and disability in the world. While current treatments prevent some of diabetes' more damaging compli ...

    SBIRPhase I2006Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government